Arecor Therapeutics plc

("Arecor" or the "Group")

ARECOR ANNOUNCES ORAL PRESENTATION OF POSITIVE AT278 PHASE 1 CLINICAL DATA AT THE EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES 2024

·    Late-breaking presentation will detail data from Phase I clinical trial of ultra-concentrated, ultra-rapid acting insulin candidate, AT278, in overweight and obese people with type 2 diabetes

Cambridge, UK, 3 September 2024: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, today announces that its abstract titled "Pharmacokinetic and pharmacodynamic properties of highly concentrated insulin aspart AT278 U500 in overweight and obese people with type 2 diabetes" has been selected as a late-breaking oral presentation at the 60^th Annual Meeting of the European Association for the Study of Diabetes (EASD), which will be held from 9-13 September 2024 in Madrid and online.

The presentation will take place on Wednesday 11 September during the SO 03 Presentation Session "One size down, three (or more) to go".

Oral Presentation:          Pharmacokinetic and pharmacodynamic properties of highly concentrated insulin aspart AT278 U500 in overweight and obese people with type 2 diabetes

Presenting Author:        Professor Thomas Pieber, Medical University of Graz, Austria

Presentation Number:  LBA 53, Station 18                           

Date and Time:               Wednesday 11 September, 12:45-13:45 (Central European Time)

AT278 (500 U/mL) is an ultra-concentrated, ultra-rapid acting, novel formulation of insulin that accelerates the absorption of insulin post injection, even when delivered at a high concentration, and hence, a lower injection volume. With no concentrated (>200 U/mL), rapid acting insulins on the market, AT278 has potential to be the first, and only, insulin available to the growing number of patients with high daily insulin requirements.

Sarah Howell, Chief Executive Officer at Arecor, said: "The recent clinical results from our second Phase I study with AT278 demonstrated superiority (PK/PD) over NovoRapid® and Humulin® R U-500 in Type 2 diabetics with a high BMI. This set of data, which builds on positive results from a previous clinical study in Type 1 diabetic patients, shows that AT278 has the potential to be the first, and only, ultra-concentrated (500 U/mL) ultra-rapid insulin product enabling miniaturisation of next-generation truly miniaturised, longer-wear insulin pumps, a key focus for patients, physicians and the industry. We look forward to Professor Thomas Pieber, Principal Investigator for the ARE-278-104 clinical trial, sharing the latest data behind this next generation insulin candidate with scientific colleagues in Madrid."

About the EASD

The European Association for the Study of Diabetes (EASD) is a non-profit, medical scientific association, founded in 1965 to encourage and support research in the field of diabetes, the rapid diffusion of acquired knowledge and to facilitate its application. EASD holds its Annual Meeting in a different European city each year with more than 15,000 delegates from over 130 countries attending. The scientific programme includes more than 1,200 talks and presentations on the latest results in diabetes research by leading experts in the field.

-ENDS-

Notes to Editors

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio. 

For further details please see our website, www.arecor.com